Publications

5803 Results

Alternative measures predicting clinical benefit in advanced non-small cell lung cancer (NSCLC) from Southwest Oncology Group (SWOG) randomized trials: implications for clincial trial design

Authors
PN Lara;MW Redman;K Kelly;MJ Edelman;SK Williamson;JJ Crowley;DR Gandara
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#7006
Year
2006
Research Committee(s)
Lung
Study Number(s)
S0003, SWOG-9509, S9806

SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel (T) versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF (G) followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer

Authors
GK Ellis;SJ Green;CA Russell;ME Royce;EA Perez;RB Livingston
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#LBA537
Year
2006
Research Committee(s)
Breast
Study Number(s)
S0012

SWOG 0338: a phase II trial of imatinib mesylate in combination with capecitabine in metastatic breast cancer.

Authors
H Chew;B Barlow;K Albain;D Lew;GT Budd;A Gown;J Gralow;RB Livingston
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#10529
Year
2006
Research Committee(s)
Breast
Study Number(s)
S0338

Sorafenib plus interferon-a2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412

Authors
CW Ryan;B Goldman;PN Lara;TM Beer;HA Drabkin;ED Crawford
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#4525
Year
2006
Research Committee(s)
Genitourinary
Study Number(s)
S0412

Surgical resection for stage IV melanoma: a Southwest Oncology Group trial (S9430)

Authors
VK Sondak;PY Liu;J Warneke;J Vetto;R Tuthill;B Redman;JA Sosman
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#8019
Year
2006
Research Committee(s)
Melanoma
Study Number(s)
SWOG-9430

A modified CA-125 progression criterion in ovarian cancer (OC) patients (pts) receiving maintenance treatment following complete clinical response (cCR) to primary therapy

Authors
P Liu;J Moon;DS Alberts;BJ Monk;M Brady;M Markman
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#5080
Year
2006
Research Committee(s)
Gynecologic
Study Number(s)
S9701

Survival (S) of ovarian cancer (OC) patients (pts) treated on SWOG9701/GOG178: 12 versus (v) 3 cycles (C) of monthly single-agent paclitaxel (PAC) following attainment of a clinically-defined complete response (CR) to platinum (PLAT)/PAC

Authors
M Markman;PY Liu;S WIlczynski;B Monk;LJ Copeland;D Alberts
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#5005
Year
2006
Research Committee(s)
Gynecologic
Study Number(s)
S9701

SWOG S0202: a phase II trial of gemcitabine and capecitabine in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinoma

Authors
S Iqbal;S McCoy;HJ Lenz;SE Rivkin;J Atkins;CD Blanke
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#4134
Year
2006
Research Committee(s)
Gastrointestinal
Study Number(s)
S0202

A phase II trial of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC); a Southwest Oncology Group (SWOG) trial.

Authors
SK Williamson;J Moon;CH Huang;P Guaglianone;GT Wolf;SG Urba
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#5550
Year
2006
Research Committee(s)
Head and Neck
Study Number(s)
S0420

A phase I pharmacokinetic (PK) study of the epothilone B analogue, ixabepilone (BMS-247550) in patients (pts) with advanced malignancies and varying degrees of hepatic impairment. a SWOG early therapeutics committee and NCI organ dysfunction working group trial

Authors
CH Takimoto;PY Liu;H Lenz;S Remick;D Mulkerin;S Mani;TW Synold;RK Ramanathan;P Ivy;AM Davies
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#2004
Year
2006
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S0355